• Avricore Health is developing a variety of pharmacy services that provide lab-quality testing for pre-diabetes and cardiovascular concerns
• The company’s trademarked HealthTab platform makes advanced testing technologies available to partner pharmacies and, through them, to patients at accessible point-of-care (“POC”) locations
• HealthTab’s partnership with Abbott Diagnostics in Canada also has the potential to expand to virus testing for COVID, RSV, influenza A and B, and strep
• The company has located the systems in Ontario and British Columbia through an agreement with large national pharmaceutical chain Shoppers Drug Mart, and anticipates expansion to other Shoppers Drug sites with 600 locations established by the end of 2023
• Avricore also expects to forge agreements that will take HealthTab’s POC testing to pharmacies in the United States, United Kingdom and European Union

Health diagnostics solutions innovator Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is celebrating its achievement of key milestones this year, building on its initial agreement with Canada’s Shoppers Drug Mart pharmaceutical chain to make its platform technology accessible to patients across the country. Avricore’s milestones include building an agreement with Abbott Diagnostics to establish in-store kiosks that utilize Avricore’s platform, allowing Avricore to test its platform in pilot stage and roll it out to the ready Shoppers Drug Mart sites. Avricore’s HealthTab platform (www.healthab.com) is a testing and health data network that draws on data from blood samples and other samples utilizing Abbott’s trademarked Afinion 2 and ID Now instruments to provide lab-quality results to patients in real time. Avricore’s mission is to make such advanced testing technologies available to its partner pharmacies. Avricore’s efforts to provide access to the testing solution makes it possible for patients to seek out pharmacies in their local neighborhoods, often within walking distance, to gain insights on critical health conditions without the additional delays associated with getting clinic appointment and then having to visit a lab. Point-of-care testing is poised to become the natural evolution of the medical industry, delivering an alternate route to health management information as pharmacists trained to dispense medications and provide vaccinations add lab testing and results oversight (https://ibn.fm/6QYZe). After testing its pilot program in Ontario, Avricore added West Coast pharmacies in British Columbia. The company’s successes in those locations have led management to forecast it will set up POC in additional Shoppers Drug Mart locations across Canada, add other pharmacies in the United States, and continue to expand to the United Kingdom and European Union (https://ibn.fm/HvOVp). The company has stated it intends to set up its POC health testing kiosks in 600 locations by the end of 2023 (https://ibn.fm/fWW6m). Its site testing is initially just providing services for pre-diabetes and cardiovascular indications, linked to Ellerca Health Corp’s app-based digital platform for chronic disease management to provide better outcomes for patients who are self-managing their illnesses (https://ibn.fm/vp2mG). But the Abbott agreement also paves the way for potential testing and reporting for COVID’s SARS-CoV-2 virus, RSV, influenza A and B, and strep at the ID Now kiosks (https://ibn.fm/f1Baf). Two key aims of Avricore’s focus on making a range of health innovations available through the community pharmacy are to improve health outcomes for patients and lower overall healthcare costs going forward. Reducing the cost of routine lab tests may ultimately help reduce costs for insurers. Insurer Blue Cross and Blue Shield of North Carolina cut $112 million in laboratory spending in 2020 through better management of the testing, according to a Modern Healthcare report (https://ibn.fm/9dVh9). “I think we have known that laboratory testing has been a driver of costs for some time,” Blue Cross’s senior medical director over clinical effectiveness, John Campbell, told Modern Healthcare. “They’re now looking at the small dollar amounts and saying listen, the volume is such here, if we decrease costs by 1 percent, that equals X amount of dollars back to the insurer,” Mick Raich, president of revenue cycle management consulting at Charlotte, North Carolina-based Lighthouse Lab Services, said in the report. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• MCOA just signed an LOI with VapeTV UK and Jasleen Enterprises for the launch of VapeTV U.S.
• This new company is set to offer in-store advertising within retail vape stores
• It will capitalize on the growing CBD industry and the ever-increasing demand for in-store media advertising in the United States

Marijuana Company of America (OTC: MCOA) has announced the signing of a non-binding letter of intent (“LOI”) that marks the beginning of the process to form a new in-store advertising brand named VapeTV US, Inc. (https://ibn.fm/lmoux). VapeTV US will be the product of a three-way partnership among cDistro, Inc, a wholly-owned MCOA distribution company, VapeTV Ltd., a United Kingdom (“UK”)-based advertising company, as well as Jasleen Enterprises LLC, the owner of Vapor Maven, one of the leading online vape shops in the United States. MCOA, through cDistro, will own 25% of the company and will capitalize on its growing customer database, coupled with Vapor Maven’s over 200 retail locations to push its services. VapeTV UK has been Europe’s leading provider of in-house media for the vaping industry. Since its inception, it has made a name for itself providing in-store display systems that run paid advertising content within retail vape stores. With the signing of this LOI, VapeTV is excited about its entry into the largely untapped United States market. “We are excited to initiate the U.S. market version of the highly successful and lucrative VapeTV business. By launching with Vapor Maven’s nearly 200 retail locations and by leveraging cDistro’s active customer database of more than 65,000 retail vape stores in the U.S., we anticipate an accelerated delivery of VapeTV advertising content to U.S. customers,” noted Mike Shaw, the Founder of VapeTV UK. VapeTV US comes in the wake of the growing competition among thousands of individual vape, smoke, and CBD brands trying to push themselves in the market. This competition is driving up the demand for in-store media advertising, an opportunity that VapeTV plans to capitalize on going forward. This move aligns with MCOA’s commitment to diversifying its product and services, given its strategic investments within the cannabis THC, hemp, and CBD industries. For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com. NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursues regulatory approval for DehydraTECH-CBD for potential use as a treatment for hypertension
• HYPER-H21-4 will build on successes witnessed in initial human hypertension studies
• The company, which has a fully funded R&D budget, recently announced new R&D programs covering multiple conditions, including dementia, diabetes, and rheumatoid disease
• Lexaria is committed to improving lives and lessening deaths through its patented DehydraTECH(TM) technology

With a fully-funded research and development (“R&D”) budget, Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed, efficacy, bioavailability, and brain absorption of orally-delivered fat-soluble active pharmaceutical ingredients (“APIs”) through its patented DehydraTECH(TM) drug delivery technology  is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors. In January 2022, Lexaria expects to report blood pressure findings from its third human hypertension study, HYPER-H21-3, building on the successes of the first two human studies, HYPER-H21-1 and HYPER-H21-2, that evidenced effective, sustained, and safe blood pressure reduction with DehydraTECH-CBD. The company will also be expecting approval from the Independent Review Board (“IRB”) for the study protocols around its fourth hypertension study. Described as the most ambitious study Lexaria has ever undertaken, HYPER-H21-4 will comprise 60 volunteers aged between 45 and 70 years, some of whom will be given three 150 mg doses of DehydraTECH-CBD daily for six weeks, while a subset will be given a placebo control. The extended duration is intended to enable the company to collect important data by monitoring the prolonged use of DehydraTECH-CBD and will investigate the potential for longer-term health benefits. “Outcomes from this study could support Lexaria’s goals related to pursuit of regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure,” said Lexaria CEO Chris Bunka in a recent press release (https://ibn.fm/t9dFj). Notably, HYPER-H21-4 is just one of the many planned studies slated for 2022. Others include HOR-A22-1, a pharmacokinetic (“PK”) study to evaluate DehydraTECH’s ability to improve the delivery characteristics of estrogen; DEM-A22-1, an efficacy modeling study to evaluate DehydraTECH-CBD with and without nicotine for the potential treatment of dementia; RHEUM-A22-1, an efficacy modeling study to investigate the ability of DehydraTECH-CBD to potentially affect the treatment of rheumatoid disease; and DIAB-A22-1, an efficacy modeling study to explore DehydraTECH-CBD’s ability to potentially impact treatment of diabetes (https://ibn.fm/JCvyu). In addition to fulfilling Lexaria’s goal to enter into new, different multi-billion-dollar markets, the four animal studies will mark the company’s push to help patients living with these conditions, some of which are potentially fatal. According to the World Health Organization (“WHO”), diabetes was the ninth leading cause of deaths globally in 2019, having claimed an estimated 1.5 million lives (https://ibn.fm/AwduP). Additionally, WHO ranks dementia as the seventh leading cause of death among all diseases and a primary cause of dependency and disability, majorly among the elderly (https://ibn.fm/BLUjc). As a versatile solution with multiple benefits, DehydraTECH is protected by a robust portfolio of 23 granted patents (currently) and more than 50 pending patents. The technology works by combining APIs with long chain fatty acid oils such as high oleic sunflower oil. The product is then added to food/carrier particles before undergoing a dehydration synthesis procedure. The final step entails rendering the final form factor of the drug as a liquid or powder. According to Lexaria, “DehydraTECH works symbiotically with existing physiological systems to enable improved and more rapid absorption into the bloodstream and brain tissues” (https://ibn.fm/mRofm). Through its focus on improving how APIs enter the bloodstream by promoting healthier delivery methods, Lexaria remains committed to improving lives and lessening deaths associated with heart disease, cigarette smoking, and, with the new R&D programs, diabetes, dementia, and more. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Date: December 4-5, 2021 Venue: Chicago Hilton, 720 South Michigan Ave, Chicago, IL Exhibit Hall Hours

• Saturday, December 4th: 11:00 A.M. to 5:00 P.M.
• Sunday, December 5th: 10:00 A.M. to 4:00 P.M.

Onsite Box Office hours begin at 9:00 a.m. each day. Cannabis cultivators, dealers, businesses, and enthusiasts are invited to attend the NECANN Illinois Cannabis Convention in Chicago, on December 4-5, 2021. Operating since 2014, NECANN events are touted as one of the largest cannabis events that are constantly expanding. The NECANN events attract a huge number of members from the Hemp, MMJ and Cannabis industries. The success of the NECANN events is attributed to the exhibitors and attendees. Anden, Columbia Care, Green Mountain Energy, and a host of other eminent start-ups will be present at this rapidly expanding convention. Participants can gain immense knowledge about the latest trends in the cannabis industry from the influencers and distinguished speakers as well as the exhibitors displaying their products and services at the NECANN Chicago. NECANN aims to bring the stalwarts of the cannabis industry under one roof at the Chicago convention. With the approval of the Illinois Cannabis Regulation and Tax Act in 2019, Illinois became the first state in the U.S. to legalize recreational marijuana sales through legislation. Illinois is estimated to produce between $2 and $4 billion in annual income from recreational sales. Since legalization, Illinois is earning an average monthly revenue of $40 million from recreational cannabis sales. Do not miss out on this phenomenal opportunity to connect with some of the biggest names in the marijuana industry in this region! NECANN offers a wonderful arena to small industries, start-ups and new cannabis growers and dealers to discover new business prospects and build networking ties with established cannabis companies and investors. In addition to the exhibit hall, there will be four full programming tracks running each day (medical, business, opportunity, social equity & justice), where attendees can learn the latest trends and technologies in the marijuana industry. The Illinois Cannabis Convention is expected to witness the largest crowd of the local medical cannabis market as well as players foraying into the new adult-use recreational market. This convention presents the best B2B and B2C platform for cannabis businesses in the state, and for those trying to carve a niche in the Illinois marijuana spectrum! In addition, this convention serves as an education platform for those interested in learning more about the vital medical marijuana program in Illinois. For more information, visit https://ibn.fm/2h0NN

• CBD-infused beverages market expected to make over $14,600 million by the end of 2026
• CBD beverages are becoming more popular as cannabis-infused goods become legalized across the United States and around the world
• Simply Sonoma has two CBD-infused beverages on the docket: an alcohol-free, CBD wine product and a low-carb, low-sugar CBD sparkling product

Cannabidiol, or CBD, is gaining the attention of enthusiastic cannabis consumers around the world. The list of products that contain CBD is growing, with one of the most popular new products being CBD-infused beverages. Simply Sonoma, a company committed to offering CBD products for the environmentally conscious consumer, is branching out into the beverage space with an alcohol-free, CBD wine product as well as low-carb, low-sugar Pinot Noir/CBD sparkling product. “The global CBD-infused beverages market was valued at around USD$3,400 million in 2020 and is expected to make over USD$14,600 million by the end of 2026, with a CAGR of approximately 27.5% between 2021 and 2026,” reported Facts and Factors (https://ibn.fm/D3gas). “The market for CBD-infused drinks is largely driven by the rising authorization and certification for recreational cannabis in countries, such as the United States and Canada. “Furthermore, because of the increasing incidence of numerous respiratory disorders, there is a growing movement away from smoking cannabis and adopting healthier edible options, which is pushing the market growth,” the article continued. “Furthermore, the common accessibility of CBD-infused drinks such as coffee, fruit punch, cannabis cola, tea, and other CBD-infused beverages across various legal marijuana outlets further augments the global industry.” Noting that CBD is the second most common active component in cannabis, the article observed that the substance is an important component of medicinal marijuana. “Despite the fact that CBD is a component of marijuana, it has no hallucinogenic effects on the human mind. ‘In people, CBD displays no effects suggestive of any misuse or dependency potential,’ according to a World Health Organization report. To date, there has been no evidence of public health issues linked to the use of pure CBD and its derivatives.” F&F reported that CBD beverages are becoming more popular as cannabis-infused goods become legalized across the United States and around the world. “CBD’s appeal has been fueled by its expanding availability combined with a growing health trend, with more and more people opting for ‘better-for-you’ alternatives to sugary drinks. CBD-infused drinks of various types provide a great alternative, with health advantages to boot, because CBD beverages are sourced from a natural source.” Simply Sonoma prides itself on using natural sources for the ingredients it uses. The company has contracted with Sonoma Biologics, a premium hemp cultivator, to grow its strains. The company also has access to some of the best grapes in the world, which Simply Sonoma is using to formulate its CBD-infused grape products. The company has two CBD-infused beverages on the docket: an antioxidant, alcohol-free, CBD wine product and a low-carb, low-sugar Pinot Noir/CBD sparkling product. Simply Sonoma is a different kind of natural company. The company is committed to creating high-quality products using all-natural, organically sun-grown, plant-based ingredients. In addition, because the company is committed to minimizing its carbon footprint, it operates off the grid, relying on solar power. For more information, or to invest in Simply Sonoma, visit the company’s website at www.SimplySonoma.org. NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma are available in the company’s newsroom at https://ibn.fm/Sonoma

• Red White & Bloom Brands is building a multi-state operation in the cannabis and hemp industries through state subsidiaries focused on markets in Florida, Michigan, Illinois, Arizona and California
• The company is now rapidly building up its cultivation and retail operations in Florida, advancing from regulatory approval in the state last month to the startup of growing activity to supply existing and soon-to-open dispensaries in four cities from Miami to Daytona Beach and across to Spring Hill
• Florida is on the verge of a “massive medical marijuana boom” as the pain-conscious retirement community grows and residents’ attitudes overwhelmingly favor openness toward legal medical marijuana
• Red White & Bloom is also putting together a strong retail cannabis position in Michigan and Florida

Multistate cannabis sector operator Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) is off to a quick start in building its high-quality flower resource for product inventory at dispensaries throughout Florida. Red White & Bloom expects to launch growing operations in 30 modular pods at its Apopka, Florida cultivation location by Dec. 1, adding 19,200 square feet of production expected to deliver $30 million in annual revenues to the company. The pods were approved by the state health department’s Office of Medical Marijuana Use (“OMMU”) with licensing granted just before Halloween and five are already in use for plant growth while the remainder are being fast-tracked for output, according to a Nov. 4 news release (https://ibn.fm/13yLA). Red White & Bloom is a retail cannabis brand builder focused on Florida ahead of a “massive medical marijuana boom” expected to sweep the state as prohibitionist policies recede (https://ibn.fm/nEZQV). “We have nurtured our strains to produce high quality flower in the Florida climate while producing high yields, industry-leading THC percentages and superior terpene content,” Jim Frazier, the general manager of Red White & Bloom’s Florida cultivation subsidiary, stated in the news release. “The grow pods provide us with speed to market capabilities which are needed for RWBFL to meet and exceed expectations for generating profitable revenue early in 2022.” The company’s two cultivation centers in Florida are working aggressively to supply existing and soon-to-open dispensaries with needed product. The final phase of Red White & Bloom’s strategic rollout in the state involves bringing its 113,000-square-foot indoor growing facility in Sanderson online, about 120 miles northwest of the Apopka location. The OMMU released a survey of the market this year that states 89 percent of Floridians who responded to its questions think adults should be allowed to legally use medical marijuana, and as more pain-weary senior citizens seek the Florida sunshine the number is likely to increase (https://ibn.fm/K6Tug). As a company aiming to become one of the top three multi-state operators active in the United States’ legal cannabis and hemp sectors, Red White & Bloom is also seeking toe-hold in the recreational adult use market in Michigan, Illinois, Florida, Arizona and California, and across of international opportunity fields for hemp. The company received adult recreational use prequalification status from Michigan in September and authorization to market itself to a population of about 10 million people through 18 dispensaries (eight of which are already operating), four cultivation facilities indoors and outdoors, and “significant company-owned real estate holdings,” according to the company’s Sept. 7 statement (https://ibn.fm/VbA0Q). “In only its second full year of adult-use sales, Michigan’s legal cannabis market is emerging from the pandemic ripe with opportunity. With a run-rate behind only California and Colorado, Michigan’s early 2021 sales have put the state on pace to not only break the $2 billion sales threshold but, also blow right past it,” CEO and Chairman Brad Rogers stated. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• StraightUp marked 2021 with strategic opportunities in the United States and Peru
• These projects were selected by management based on past exploration and proven reserves in these regions
• 2021 also marked the year StraightUp up-listed to the OTCQB Venture Market in the United States
• StraightUp is optimistic about 2022

For the 2021 fiscal and calendar year, StraightUp Resources (CSE: ST) (OTCQB: STUPF) set out on an aggressive asset acquisition plan, coupled with an exploration program that would be the highlight of the year. Thus far, it has acquired the West Cat Mine in Nevada, along with the Ferdinand Gold Project and Bear Head Gold Project, both located in western Ontario (https://ibn.fm/kPFqY). However, these acquisitions do not aptly represent its commitment to maximizing shareholder wealth as its aggressive exploration program. StraightUp, at the beginning of the year, broke down its 2021 exploration program into four elements:

1. Historical data review, compilation, and interpretation
2. Examining historical drill core (ENDM core library, Red Lake)
3. Geological mapping and sampling
4. Geophysical surveys

The objective was to add new 2021 data to enhance interpretations, locate prime locations for drilling holes and conduct soil sampling to inform the company’s investment decisions and guarantee a return on its investment. This exploration program was firmly founded on science, mainly SGH soil sampling, primitive-mantle normalized trace element geochemistry, and geophysical surveys, among others (https://ibn.fm/90yBO). So far, these efforts have allowed StraightUp to acquire prime properties with tremendous potential to maximize shareholder wealth. It has also allowed the company to expand its market reach, with its entry into the American market with the West Cat Mine acquisition in Nevada and the Peruvian market with the exclusive rights to purchase of the Mallay silver mine. StraightUp also made a significant move to expand its access to investors by up-listing to the OTCQB Venture Market in the United States (https://ibn.fm/urNtt). It comes just in time as the company grows its asset portfolio, opening its doors to millions of investors within the United States, particularly as it plans to execute on its next phase of growth. In addition, the company hopes to benefit shareholders through increased trading liquidity through this move, ultimately adding more value for them and their investment. Over the past year, the company has made some important gains and its management has expressed optimism for the 2022 financial year in growing shareholder value. For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF

• Rositano Jr. is looking for the Fan Pass Live artist platform to expand its global reach and become a household name in the near future
• The live interview put Fan Pass into the spotlight and introduced the platform to Hype’s estimated audience of 300,000 readers and its social media following of over 484k on Instagram and over 189k on Twitter
• Rositano Jr. made it clear during the interview that great things are planned from Friendable for the Fan Pass platform in the new year

Music has always found a place in the lives of Robert A. Rositano Jr. and his brother (and business partner) Dean. Growing up, Dean was a touring musician, and as a family, the Rositanos have always been enchanted by artists and the music industry. In a recent interview with The Hype Magazine, Rositano Jr., the CEO of Friendable (OTC: FDBL), sat down for a live discussion with the magazine’s Editor-in-Chief, Jerry Doby, to discuss his company’s innovative artist streaming platform, from inception to plans for the future (https://ibn.fm/Vu4bs). The Hype Magazine has an audience reach of over 300,000, with 484k followers on Instagram and over 189k Twitter followers. The company is hoping to use this interview and the fan base of The Hype Magazine to extend the exposure of the Fan Pass platform and its offering to both fans and artists. “First, I’d like to thank our team at Lobeline Communications for seeking out this industry-specific opportunity to share the Fan Pass story, platform, and opportunity with the music artist community. The traction and attention received by the company since onboarding the Lobeline team have been very apparent as we collectively continue elevating our brand and making strides on many levels,” explained Rositano Jr. The interview presented informative talking points, spanning the history of past applications and the birth of the Fan Pass platform to what the company’s vision for five years in the future might look like. The Rositano brothers began working with artists before the concept of live streaming even existed. The vision eventually turned into “America’s Biggest” in 2005. Artists would record music in a San Francisco studio, where it would be archived onto a website. A $5k pool would be offered each month and given to the winner of what Rositano Jr. referred to as “an offline battle of the bands.” The platform only lasted 90 days before another company acquired it but never fulfilled its full potential after being sold. Fan Pass was already in the works long before the pandemic reared its ugly head. In fact, the pandemic forced the company to regroup and figure out how they could retarget the entire platform to better serve the artists and fans who were suffering because of it. Even with all of the new features that have been released this year, Rositano Jr. hinted about several opportunities coming with 2022. One of these opportunities involves artists being included on playlists through partnerships with celebrities – but Rositano Jr. remained tight-lipped on the matter, saying that he was not ready to disclose any more details about it at this point. Doby also asked about Fan Pass going global, to which Rositano Jr. responded that the platform is currently #70 in Vietnam, so going international is certainly an opportunity they plan to explore in the coming months. As for the future, Rositano Jr. has high hopes for the Fan Pass Live artist platform. Five years from now, he wants to see Fan Pass become a household name with hundreds of thousands of artists launching their careers and earning revenue through the platform. The Friendable CEO hopes that even though venues are beginning to reopen, artists will be willing to augment their tours to include virtual performances, if for no other reason than to accommodate those who are hesitant to go to a live performance or those who can’t afford the traditional VIP experience. He concluded by saying it was very exciting to be interviewed by a publication that truly understands the music industry, musicians, and more specifically, indie artists, like The Hype Magazine does. “We intend to continue nurturing a relationship that expands beyond this initial interview, as indie artists are seeking a solution that brings recognition, builds fan bases, drives revenue, and, ultimately, launches careers,” Rositano Jr. underlined. “We believe Fan Pass is the solution. A new year is upon us shortly, and we have lots in store as we continue to build on our success.” For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• LQwD’s proprietary, multi-pronged Lightning Network platform provides easier access to a decentralized network and payment solution
• The platform makes it possible for users to create and manage Lightning Network nodes easily; make transactions securely, privately, and almost instantaneous; create channels on the Network with effective routing; request and manage liquidity more efficiently
• Bitcoin experts have predicted that the price of the cryptocurrency will continue to climb through 2021, potentially hitting highs around USD$80,000 before surging to USD$250,000 by 2025 and a goal of USD$5 million per Bitcoin by 2030
• The Lightning Network is a second-layer protocol sitting above the Bitcoin blockchain and will advance Bitcoin from a store-of-value to a global monetary network through payment utility. LQwD expects the Network to increase the growing number of active blockchain wallets by increasing Bitcoin scalability, transaction speeds and lowering fees

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a financial technology company with a mission of developing institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption, and the utility and scalability of Bitcoin, has announced the launch of its proprietary multi-pronged, Lightning Network Software as a Service (SaaS) – LQwD.tech. The platform provides easier access to a decentralized network and payment solution. This SaaS will allow B2B markets, investors, and others to gain broader access, more efficient liquidity, and seamless usage of the global payments infrastructure. The platform creates the potential for multiple nodes across channels, with the potential to lower transaction fees and a more user-friendly option (https://ibn.fm/HXWz6). Tune into LQwD CEO, Shone Anstey discusses the recently launched platform here. “The Lightning Network is an extremely dynamic new global monetary network that’s growing exponentially, and we’re excited and fortunate to be a solutions provider in the space,” Albert Szmigielski, LQwD’s Chief Technology Officer, said. Szmigielski explained that developing countries such as El Salvador are using and seeing significant adoption of cryptocurrencies, while one of the world’s largest social media platforms – Twitter – is making global tipping on the Lightning Network mainstream with its tipping feature called Tips. “Needless to say, we’re looking forward to becoming a major contributor to (and supporter of) Bitcoin’s scaling layer – the Lightning Network.” With the launch of LQwD.tech, the company will deploy a portion of its Bitcoin holdings to secure additional nodes and provide liquidity to the platform, enabling LQwD to earn transaction fees on the rapidly growing payment network. This platform empowers institutions, businesses, and investors, making integration with the Lightning Network easy. The design was created to be scalable and adaptive to the incredible growth of the Lightning Network, which allows for millions of Bitcoin transactions in seconds. LQwD’s platform makes it possible for users to:

• Easily create and manage Lightning Network nodes
• Make transactions securely, privately, and almost instantly using the Network
• Create channels on the Network with effective routing
• Request and manage liquidity more efficiently

Cryptocurrency experts have predicted that the price of Bitcoin will continue to climb through 2021, potentially hitting highs around $80,000 before surging to $250,000 by 2025 and a goal of $5 million per Bitcoin by 2030 (https://ibn.fm/m9TZr). The Lightning Network is a second-layer protocol sitting above the Bitcoin blockchain and will advance Bitcoin from a store-of-value to a global monetary network through payment utility. LQwD expects the Network to increase the growing number of active blockchain wallets by increasing Bitcoin scalability and lowering fees. The Network is intended to facilitate faster micro-transactions, thus allowing for the mass adoption of Bitcoin. For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• Pharmaceutical company Tryp Therapeutics is investigating the potential of synthetic psychedelic drug candidates to treat unmet medical needs
• The company is evaluating two drug products labeled TRP-8802 and TRP-8803 for treating fibromyalgia, phantom limb pain, complex regional pain syndrome and select eating disorders
• The company has filed its first two INDs with the FDA for planned Ph 2a clinical trials relating to fibromyalgia and eating disorder treatments
• In the wake of changes recommended by the FDA to the eating disorders trial, Tryp is in the process of updating its protocols and patient consent form to meet the FDA’s expectations
• Tryp anticipates completing preparations for the phantom limb pain and complex regional pain syndrome studies in partnership with investigators in the University of California system

Pioneering psychedelic medicine pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is advancing toward the launch of four Phase 2a studies of its two novel drug candidates, laying the groundwork for clinical trials at the University of Michigan and the University of Florida for treating pain and eating disorders, which includes making some adjustments to one of the trials recently requested by the FDA. Tryp’s synthetic psilocybin program includes the development of drug candidates TRP-8802 and TRP-8803 for treating fibromyalgia, phantom limb pain, complex regional pain syndrome (“CRPS”) and select eating disorders. Tryp filed an IND with the U.S. Food and Drug Administration in September for treating overeating disorders in Florida, and filed its second IND application earlier this month for fibromyalgia testing in Michigan (https://ibn.fm/fzSc4). The FDA asked Tryp to change the scope of its eating disorders trial so that the initial Florida investigation can focus on patients with binge eating disorder. Because the company was also planning to recruit patients with a range of overeating disorders including Prader-Willi Syndrome (“PWS”) and hypothalamic obesity disorder resulting from the removal of a brain tumor, the FDA asked the company to break off the hypothalamic obesity disorder testing and file a separate IND for a potential fifth clinical study regarding those patients. “We appreciate the feedback from the FDA on our clinical activities for binge eating disorder and hypothalamic obesity patients,” Tryp Chairman and CEO Greg McKee stated in a Nov. 18 news release (https://ibn.fm/JzrbX). “We look forward to advancing our synthetic psilocybin programs for the benefit of patients and clinicians alike.” McKee stated the company would submit a formal response to the FDA within 10 days of the news release outlining changes to the eating disorders clinical trial and its informed consent form, and added that the FDA indicated it would respond to those modifications within 30 days. McKee told Trader TV that the company is excited to begin dosing patients in the Florida eating disorder study and the Michigan fibromyalgia study as soon as the final steps are taken care of, and that the company is working with educational partners in the University of California system to prepare for the anticipated phantom limb pain and CRPS trial filings (https://ibn.fm/qN79d). “Compared to other companies in the psychedelic drug development space, we’re going to have these four phase 2a clinical trials, which puts us in pretty rarefied air on top of the fact that we’re working in some therapeutic areas with patients that that really not a lot of other companies are looking at this time,” McKee said. The clinical trials will use TRP-8802. TRP-8803 will be developed as a proprietary, synthetic psilocybin drug candidate designed to advance the company through Phase 2b clinical trials that evaluate the drug candidate’s ability to penetrate the natural blood-brain barrier to more effectively alleviate pain and addiction, using a novel route of administration that will lead to more precise control over the patient’s psychedelic experience during the treatment. Tryp plans to administer TRP-8802 in 25 mg oral dosing, and was enthused by the report of Compass Pathways at the recent Wonderland: Miami conference where Compass reported its own success using 25 mg oral dosing of psilocybin in combination with psychotherapy to treat resistant depression, which Tryp regards as validation of its hypothesis (https://ibn.fm/tdtpR). For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF